CAMP4 to Present at the 44th Annual J.P. Morgan Healthcare Conference

Core Viewpoint - CAMP4 Therapeutics is a clinical-stage biopharmaceutical company focused on developing RNA-targeting therapeutics aimed at treating genetic diseases by restoring healthy protein levels [1][3]. Group 1: Corporate Update - Josh Mandel-Brehm, President & CEO of CAMP4, will present a corporate update at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 3:45 p.m. PST [1]. - The presentation will be available via webcast on CAMP4's investor relations page, with a replay accessible for 30 days post-conference [2]. Group 2: Company Overview - CAMP4 is developing disease-modifying treatments for over 1,200 genetic diseases where increasing healthy protein levels may provide therapeutic benefits [3]. - The company's approach involves amplifying mRNA by targeting regulatory RNAs (regRNAs), which are crucial for gene expression control [3]. - CAMP4's proprietary RAP Platform facilitates the mapping of regRNAs and the creation of therapeutic candidates aimed at addressing haploinsufficient and recessive partial loss-of-function disorders [3].